Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Curr Opin Pharmacol. 2010 Feb;10(1):14-22. doi: 10.1016/j.coph.2009.10.010. Epub 2009 Nov 26.
The intramembrane receptor-receptor interactions among GPCRs demonstrated in the beginning of the 80s in the CNS probably reflect the existence of allosteric mechanisms in receptor heteromers, and the postulated assemblies of multiple GPCRs coined 'receptor mosaics' in the early 80s probably represent higher order receptor heteromers, recently demonstrated with novel biophysical techniques in living cells. The receptor interface in the GPCR heteromers is beginning to be characterized and in adenosine A(2A)-dopamine D(2)-like heteromers the electrostatic arginine-phosphate salt bridge seems to be a hot spot in the interface with covalent-like stability, possibly participating in the allosteric interactions and making possible integration of heteromer receptor function. We discuss the possible relevance of some putative D(2) receptor heteromers in the treatment of Parkinson's disease and schizophrenia, respectively.
80 年代初在中枢神经系统中发现的 GPCR 跨膜受体-受体相互作用可能反映了受体异源二聚体中变构机制的存在,而 80 年代初提出的多种 GPCR 组合“受体镶嵌”可能代表了更高阶的受体异源二聚体,最近在活细胞中使用新的生物物理技术得到了证实。GPCR 异源二聚体的受体界面开始被表征,在腺苷 A(2A)-多巴胺 D(2)样异源二聚体中,静电精氨酸-磷酸盐桥似乎是界面上的一个热点,具有类似共价键的稳定性,可能参与变构相互作用并使异源二聚体受体功能的整合成为可能。我们讨论了一些假定的 D(2)受体异源二聚体在帕金森病和精神分裂症治疗中的可能相关性。